These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

262 related items for PubMed ID: 21150467

  • 1. Randomized phase II trial of irinotecan with paclitaxel or gemcitabine for non-small cell lung cancer: association of UGT1A1*6 and UGT1A1*27 with severe neutropenia.
    Nakamura Y, Soda H, Oka M, Kinoshita A, Fukuda M, Fukuda M, Takatani H, Nagashima S, Soejima Y, Kasai T, Nakatomi K, Masuda N, Tsukamoto K, Kohno S.
    J Thorac Oncol; 2011 Jan; 6(1):121-7. PubMed ID: 21150467
    [Abstract] [Full Text] [Related]

  • 2. Randomized phase III study of cisplatin plus irinotecan versus carboplatin plus paclitaxel, cisplatin plus gemcitabine, and cisplatin plus vinorelbine for advanced non-small-cell lung cancer: Four-Arm Cooperative Study in Japan.
    Ohe Y, Ohashi Y, Kubota K, Tamura T, Nakagawa K, Negoro S, Nishiwaki Y, Saijo N, Ariyoshi Y, Fukuoka M.
    Ann Oncol; 2007 Feb; 18(2):317-23. PubMed ID: 17079694
    [Abstract] [Full Text] [Related]

  • 3. Randomized phase II trial of gemcitabine plus irinotecan or docetaxel in stage IIIB or stage IV NSCLC.
    Rocha Lima CM, Rizvi NA, Zhang C, Herndon JE, Crawford J, Govindan R, King GW, Green MR, Cancer Leukemia Group B.
    Ann Oncol; 2004 Mar; 15(3):410-8. PubMed ID: 14998842
    [Abstract] [Full Text] [Related]

  • 4. Comprehensive analysis of UGT1A polymorphisms predictive for pharmacokinetics and treatment outcome in patients with non-small-cell lung cancer treated with irinotecan and cisplatin.
    Han JY, Lim HS, Shin ES, Yoo YK, Park YH, Lee JE, Jang IJ, Lee DH, Lee JS.
    J Clin Oncol; 2006 May 20; 24(15):2237-44. PubMed ID: 16636344
    [Abstract] [Full Text] [Related]

  • 5. Weekly regimen of irinotecan/docetaxel in previously treated non-small cell lung cancer patients and correlation with uridine diphosphate glucuronosyltransferase 1A1 (UGT1A1) polymorphism.
    Font A, Sánchez JM, Tarón M, Martinez-Balibrea E, Sánchez JJ, Manzano JL, Margelí M, Richardet M, Barnadas A, Abad A, Rosell R.
    Invest New Drugs; 2003 Nov 20; 21(4):435-43. PubMed ID: 14586211
    [Abstract] [Full Text] [Related]

  • 6. Salvage treatment with irinotecan/cisplatin versus pemetrexed/cisplatin in patients with non-small cell lung cancer pre-treated with a non-platinum-based regimen in the first-line setting: a randomized phase II study of the Hellenic Oncology Research Group (HORG).
    Kentepozidis N, Economopoulou P, Christofyllakis C, Chelis L, Polyzos A, Vardakis N, Koinis F, Vamvakas L, Katsaounis P, Kalbakis K, Nikolaou C, Georgoulias V, Kotsakis A.
    Clin Transl Oncol; 2017 Mar 20; 19(3):317-325. PubMed ID: 27492015
    [Abstract] [Full Text] [Related]

  • 7. A phase I-II study of bi-weekly gemcitabine and irinotecan as second-line chemotherapy in non-small cell lung cancer after prior taxane + platinum-based regimens.
    Kosmas C, Tsavaris N, Syrigos K, Koutras A, Tsakonas G, Makatsoris T, Mylonakis N, Karabelis A, Stathopoulos GP, Kalofonos HP.
    Cancer Chemother Pharmacol; 2007 Jan 20; 59(1):51-9. PubMed ID: 16622691
    [Abstract] [Full Text] [Related]

  • 8. [A prospective randomized controlled clinical trial of irinotecan plus cisplatin versus gemcitabine plus cisplatin as a first-line treatment for advanced non-small cell lung cancer].
    Zhao WY, Chen DY.
    Zhonghua Zhong Liu Za Zhi; 2012 Oct 20; 34(10):775-9. PubMed ID: 23291073
    [Abstract] [Full Text] [Related]

  • 9. A phase II trial of weekly chemotherapy with paclitaxel plus gemcitabine as a first-line treatment in advanced non-small-cell lung cancer.
    Mori K, Kobayashi H, Kamiyama Y, Kano Y, Kodama T.
    Cancer Chemother Pharmacol; 2009 Jun 20; 64(1):73-8. PubMed ID: 18941748
    [Abstract] [Full Text] [Related]

  • 10. Gemcitabine and docetaxel as second-line chemotherapy for patients with nonsmall cell lung carcinoma who fail prior paclitaxel plus platinum-based regimens.
    Kosmas C, Tsavaris N, Vadiaka M, Stavroyianni N, Koutras A, Malamos N, Onyenadum A, Rokana S, Polyzos A, Kalofonos HP.
    Cancer; 2001 Dec 01; 92(11):2902-10. PubMed ID: 11753965
    [Abstract] [Full Text] [Related]

  • 11. Vinorelbine plus gemcitabine followed by docetaxel versus carboplatin plus paclitaxel in patients with advanced non-small-cell lung cancer: a randomised, open-label, phase III study.
    Kubota K, Kawahara M, Ogawara M, Nishiwaki Y, Komuta K, Minato K, Fujita Y, Teramukai S, Fukushima M, Furuse K, Japan Multi-National Trial Organisation.
    Lancet Oncol; 2008 Dec 01; 9(12):1135-42. PubMed ID: 19013107
    [Abstract] [Full Text] [Related]

  • 12. New triplet chemotherapy combination with carboplatin, paclitaxel and gemcitabine plus amifostine support in advanced non small cell lung cancer: a phase II study.
    Illiano A, Barletta E, De Marino V, Battiloro C, Barzelloni M, Scognamiglio F, Rossi N, Zampa G, De Bellis M, Gridelli C.
    Anticancer Res; 2000 Dec 01; 20(5C):3999-4003. PubMed ID: 11268491
    [Abstract] [Full Text] [Related]

  • 13. Phase II multicenter trial with carboplatin and gemcitabine induction chemotherapy followed by radiotherapy concomitantly with low-dose paclitaxel and gemcitabine for stage IIIA and IIIB non-small cell lung cancer.
    Hirsh V, Soulieres D, Duclos M, Faria S, Del Vecchio P, Ofiara L, Ayoub JP, Charpentier D, Gruber J, Portelance L, Souhami L.
    J Thorac Oncol; 2007 Oct 01; 2(10):927-32. PubMed ID: 17909355
    [Abstract] [Full Text] [Related]

  • 14. Randomized phase 2 study of irinotecan plus cisplatin versus gemcitabine plus vinorelbine as first-line chemotherapy with second-line crossover in patients with advanced nonsmall cell lung cancer.
    Han JY, Lee DH, Song JE, Lee SY, Kim HY, Kim HT, Lee JS.
    Cancer; 2008 Jul 15; 113(2):388-95. PubMed ID: 18484595
    [Abstract] [Full Text] [Related]

  • 15. Gemcitabine and vinorelbine followed by weekly docetaxel in patients with advanced non-small-cell lung cancer: a phase II trial of sequential chemotherapy.
    Cobo Dols M, Villar Chamorro E, Alés Díaz I, Gil Calle S, Alcalde García J, Gutiérrez Calderón V, Carabantes Ocón F, Montesa Pino A, Bretón García JJ, Benavides Orgaz M.
    Clin Transl Oncol; 2006 Oct 15; 8(10):742-9. PubMed ID: 17074673
    [Abstract] [Full Text] [Related]

  • 16. Phase I/II study of paclitaxel, gemcitabine and vinorelbine as first-line chemotherapy of non-small-cell lung cancer.
    Lorusso V, Crucitta E, Panza N, Silvestris N, Guida M, Carpagnano F, Mancarella S, Sambiasi D, De Lena M.
    Ann Oncol; 2002 Dec 15; 13(12):1862-7. PubMed ID: 12453853
    [Abstract] [Full Text] [Related]

  • 17. Phase II clinical trial with gemcitabine and paclitaxel sequential monotherapy as first-line treatment for advanced non-small-cell lung cancer (SLCG 01-04).
    Iranzo V, Sirera R, Carrato A, Cabrera A, Jantus E, Guijarro R, Sanmartín E, Blasco A, Gil M, Gómez-Aldaraví L, González-Larriba JL, Massuti B, Velasco A, Provencio M, Rossell R, Camps C.
    Clin Transl Oncol; 2011 Jun 15; 13(6):411-8. PubMed ID: 21680302
    [Abstract] [Full Text] [Related]

  • 18. Challenging the platinum combinations in the chemotherapy of NSCLC.
    Douillard JY, Eckardt J, Scagliotti GV.
    Lung Cancer; 2002 Dec 15; 38 Suppl 4():21-8. PubMed ID: 12480191
    [Abstract] [Full Text] [Related]

  • 19. Efficacy of the combination of cisplatin with either gemcitabine and vinorelbine or gemcitabine and paclitaxel in the treatment of locally advanced or metastatic non-small-cell lung cancer: a phase III randomised trial of the Southern Italy Cooperative Oncology Group (SICOG 0101).
    Comella P, Filippelli G, De Cataldis G, Massidda B, Frasci G, Maiorino L, Putzu C, Mancarella S, Palmeri S, Cioffi R, Roselli M, Buzzi F, Milia V, Gambardella A, Natale D, Bianco M, Ghiani M, Masullo P, Southern Italy Cooperative Oncology Group.
    Ann Oncol; 2007 Feb 15; 18(2):324-30. PubMed ID: 17071935
    [Abstract] [Full Text] [Related]

  • 20. ERCC1 Expression-Based Randomized Phase II Study of Gemcitabine/Cisplatin Versus Irinotecan/Cisplatin in Patients with Advanced Non-small Cell Lung Cancer.
    Han JY, Lee GK, Lim KY, Lee YJ, Nam BH, Lee JS.
    Cancer Res Treat; 2017 Jul 15; 49(3):678-687. PubMed ID: 27737534
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.